Jamjoom Pharmaceuticals Factory Co. · TADAWUL:4015
Jamjoom Pharmaceuticals Factory — Q1 2025 Earnings Presentation
17 slides from Jamjoom Pharmaceuticals Factory's earnings presentation, Apr 30, 2025
Slide 1: Earnings Presentation Q1 2025
Earnings Presentation Q1 2025 Jeddah | 30 April 2025
Slide 2: Disclaimer
2 Disclaimer This presentation has been prepared solely for use as an investor presentation for Jamjoom Pharmaceuticals Factory Company (the “Company”). By attending or by reading this presentation, you agree to be bound by the following limitations. The information contained in this presentation is
Slide 3: Business and Strategy Highlights
Business and Strategy Highlights
Slide 4: 1Q 2025 Highlights: Highest ever quarterly revenue and profitability
4 Business and Strategy Highlights 1Q 2025 Highlights: Highest ever quarterly revenue and profitability Revenue Our strongest quarterly sales performance to # of Brands 2 new launches date, underpinned by continued success in 1Q 25 +19% YoY 1Q 25 +7 YoY +1 in Anti-Diabetic strategic delivery across
Slide 5: 1st Quarter 2025 in focus
5 Business and Strategy Highlights 1st Quarter 2025 in focus • As per IQVIA, KSA retail market1 grew +13% in MAT Q1 2025 (JP grew 17%) Saudi Market • Successful execution of commercial strategy to further bolster market share growth in home market • Iraq (+17%) and Gulf (+16%) continue to make solid
Slide 6: Jeddah Main Facility transfers pace ramp up of new facilities
6 Business and Strategy Highlights Jeddah Main Facility transfers pace ramp up of new facilities SAR 100bn+ of Total Addressable Market Jeddah Jeddah Cairo Algiers* in Core Geographies By 2027 Main Facility Sterile Facility Main Facility Facility Iraq Kuwait Bahrain Egypt Qatar Kingdom of Saudi Arab
Slide 7: Consistent revenue growth in core therapeutic areas and key markets
7 Business and Strategy Highlights Consistent revenue growth in core therapeutic areas and key markets Revenue Contribution by Therapeutic Area, YoY (SARmn) Revenue Contribution by Country, YoY (SARmn) +19% +19% 9 6 3 0 458 21 15 20 (0) 385 (1) 62 7 6 4 458 385 (7) Focus on driving strategic Self-su
Slide 8: Expanding beyond niche: JP's portfolio diversification into high-value TAs
8 Business and Strategy Highlights Expanding beyond niche: JP’s portfolio diversification into high-value TAs 2021 Revenue Contribution by Therapeutic Area (SARmn) 1Q 2025 Revenue Contribution by Therapeutic Area (SARmn) Pain & Inflammation 26% C. Nervous System 5% Anti-diabetic Ophthalmology Ophtha
Slide 9: Positioning JP for long-term growth through strategic business development
9 Business and Strategy Highlights Positioning JP for long-term growth through strategic business development Eight new agreements signed across high-growth therapeutic areas, strengthening market leadership and supporting long-term growth ambitions, commercial launches expected late-2026 onwards #
Slide 10: Pipeline overview
10 Business and Strategy Highlights Pipeline overview Under SFDA review Ready for SFDA Submission Under Development Total 2 Ophthalmology 6 15 7 2 General Medicine 1 3 Revenue growth EBITDA Dermatology 4 margin 1 3 1 Gastrointestinal 3 6 2 Cardiovascular 2 9 7 Cardiometabolic TAs 3 17 Anti-diabetes
Slide 11: Key sustainability highlights and ongoing commitments
11 Business and Strategy Highlights Key sustainability highlights and ongoing commitments Enabling affordable Sustainable Thriving workforce manufacturing and Responsible governance access to healthcare operations Invested ~3% of 2024 Partnered with the King 100% of operations are ISO 25.35% female
Slide 12: Financial Highlights
Financial Highlights
Slide 13: 1st Quarter 2025 highlights
13 Financial Highlights 1st Quarter 2025 highlights Revenue (SARmn) EBITDA (SARmn) +19% +26% 458 172 385 137 EBITDA Margin 35.4% 37.7% 1Q 24 1Q 25 1Q 24 1Q 25 Gross Profit (SARmn) Net Profit (SARmn) +17% +53% 293 157 249 103 driven by improved operational efficiency and absence of devaluation impact
Slide 14: Operational efficiency to counter rising costs…
14 Financial Highlights Operational efficiency to counter rising costs… Total Cost Of Revenue Movement YoY (SARmn) Operating Expenses Movement YoY (SARmn) +11% +21% 1 5 6 132 119 3 165 Maintained S&D/Sales Maintained 7 R&D/Sales YoY down 3pps YoY G&A/Sales YoY 20 (1) +16% +6% +38% 136 1Q 24 R&D Sell
Slide 15: … and delivering an even healthier growth in profitability
15 Financial Highlights … and delivering an even healthier growth in profitability EBITDA Movement YoY (SARmn) Quarterly Trend of Profitability (%) +26% 64.7% 64.0% 63.1% 61.0% EBITDA Margin 59.3% 72 37.7% EBITDA Margin 35.4% 4 172 (29) (5) (6) 137 37.7% 35.4% 33.8% 34.1% Successful operating 27.7%
Slide 16: Scaling working capital to fuel high-growth trajectory
16 Financial Highlights Scaling working capital to fuel high-growth trajectory ▪ Cash conversion cycle expanded by a CAGR of 6.3% since 1Q 2023 to support Cash Conversion Cycle (Days) revenue growth, ensuring inventory availability, customer flexibility, and supplier trust +13% ▪ Working capital amo
Slide 17: Q&A
Q&A Tarek Hosni, Chief Executive Officer Anwer Mohiuddin, Chief Financial Officer Muhammad Bin Khalid, Assoc. Director – Finance & IR
Jamjoom Pharmaceuticals Factory — Q1 2025 Earnings Presentation on 6ix